Safe Pharmacologic Management of Allergic Rhinitis in Pregnancy

First‑Line Therapies

• Intranasal corticosteroids are safe and effective throughout pregnancy, offering superior efficacy with minimal systemic absorption; evidence from multiple cohort studies and meta‑analyses supports their use. [1][2]3
• Budesonide is the preferred intranasal corticosteroid because it has the most extensive human safety data and is classified as Pregnancy Category B; this recommendation is based on large‑scale safety registries. [2][3]4
• Other intranasal corticosteroids (beclomethasone, fluticasone propionate, mometasone) have not shown convincing evidence of congenital defects in pregnancy. [1][3]
• Meta‑analyses demonstrate no increased risk of major malformations, preterm delivery, low birth weight, or pregnancy‑induced hypertension with intranasal corticosteroid use. [1][3]
• The lowest effective dose of intranasal corticosteroid should be used to maintain symptom control, as advised by dose‑optimization studies. [2][3]
• Cetirizine and loratadine are the preferred oral antihistamines during pregnancy, supported by robust safety data from large observational cohorts. [5][6]
• Second‑generation antihistamines provide safety comparable to first‑generation agents while avoiding sedative and anticholinergic side effects; this is based on comparative safety analyses. [5][7]

Additional Safe Options

• Saline nasal rinses are safe throughout pregnancy and are recommended as adjunctive therapy; safety is confirmed in prospective pregnancy studies. [8][9]10
• Sodium cromolyn (Pregnancy Category B) is safe but requires frequent dosing (four times daily) and has limited efficacy compared with intranasal corticosteroids; evidence comes from controlled trials. [1][2]
• Montelukast (Pregnancy Category B) may be used if the patient had a favorable pre‑pregnancy response, especially when asthma is present; recommendation is based on cohort data and expert consensus. [5][1][2][4]
• Limited case series (n ≈ 9) reported no adverse events with montelukast, though larger studies are needed for definitive safety conclusions. [1][2]
• Montelukast should not be first‑line for rhinitis alone but can be continued if already effective for the patient. [9][2]3
• Allergen immunotherapy should be continued if already initiated before pregnancy, without dose escalation; this guidance is derived from longitudinal immunotherapy registries. [5][7]3
• Initiating new immunotherapy or increasing doses during pregnancy is discouraged due to the risk of anaphylaxis, as shown in safety monitoring reports. [5][9]3

Medications to Avoid

• Oral decongestants (phenylephrine, pseudoephedrine) should be avoided in the first trimester because of associations with gastroschisis, small‑intestinal atresia, and cardiac anomalies; evidence stems from case‑control studies. [5][7][6][1]
• The teratogenic risk of oral decongestants increases when combined with acetaminophen or salicylates; this interaction is documented in pharmacovigilance analyses. [6][1]
• Oral decongestants may also contribute to maternal hypertension, as reported in observational cohorts. [8][9]
• Diphenhydramine has been linked to cleft palate in some studies, although more recent data are reassuring; the association is based on mixed‑design epidemiologic research. [5][7]6
• Hydroxyzine should be avoided in the first trimester, based on animal teratogenicity data and limited human evidence. [5][6]1
• First‑generation antihistamines are generally avoided because of sedative and anticholinergic effects, supported by safety reviews. [8][9]
• Intranasal antihistamines (e.g., azelastine) lack sufficient safety data and should be avoided during pregnancy; this recommendation follows precautionary principle guidelines. [5][7]

Treatment Algorithm by Severity

• Mild intermittent symptoms: Begin with saline nasal rinses; add cetirizine or loratadine if needed. Evidence from practice‑based studies supports this stepwise approach. [8][9][10][5]
• Mild‑to‑moderate persistent symptoms: Use intranasal budesonide as first‑line; add cetirizine or loratadine if response is inadequate; consider sodium cromolyn for patients preferring non‑steroidal options. Recommendations are based on comparative effectiveness trials. [1][2][3][5]6
• Moderate‑to‑severe persistent symptoms: Combine intranasal corticosteroid (budesonide preferred) with an oral second‑generation antihistamine; add montelukast when asthma co‑exists or when prior response was favorable. Supported by cohort and expert consensus data. [5][1][3][2]
• Severe exacerbations: Short‑course oral corticosteroids may be used after the first trimester if benefits outweigh risks, especially with concurrent asthma exacerbation; obstetric consultation is required. Guidance derives from risk‑benefit analyses. 10

Critical Timing Considerations

• The first trimester represents the period of greatest concern for teratogenicity during organogenesis; oral decongestants and hydroxyzine should be strictly avoided during this window. [5][7][6][1]
• FDA pregnancy categories are primarily based on animal studies and limited human data; clinicians should prioritize human cohort and registry evidence when available. [7][6]
• Combination products containing decongestants with acetaminophen or salicylates carry higher malformation risks and should be avoided throughout pregnancy. [6][1]
• Overall, human safety data consistently support intranasal corticosteroids and select second‑generation antihistamines as the safest and most effective pharmacologic options for allergic rhinitis across all trimesters. [5][6][1][3]

Intranasal Corticosteroid Use in Pregnancy – Evidence‑Based Guidance

Safety Profile of Intranasal Corticosteroids

• Mometasone nasal spray can be continued safely during pregnancy when it already provides adequate symptom control, but budesonide is the preferred first‑line agent for new therapy because of more extensive human safety data. (moderate‑quality evidence) 11, 12, 13
• Human safety data for mometasone in pregnancy are very limited compared with other intranasal corticosteroids. (low‑quality evidence) 11, 12, 13, 14
• No convincing association has been found between intranasal or inhaled corticosteroid use—including mometasone—and congenital malformations. (moderate‑quality evidence) 11, 12, 13, 15
• Meta‑analyses of inhaled corticosteroids show no increased risk of major malformations, preterm delivery, low birth weight, or pregnancy‑induced hypertension. (high‑quality evidence) 11, 12, 13, 14
• Intranasal corticosteroids achieve markedly lower systemic exposure than orally inhaled corticosteroids, supporting a favorable safety profile in pregnancy. (moderate‑quality evidence) 11, 12, 13, 15
• The minimal systemic absorption of mometasone furoate further reduces theoretical fetal risk while preserving local efficacy. (low‑quality evidence) 11

Treatment Recommendations

Patients Already Using Mometasone Pre‑Pregnancy

• Continue mometasone if it has been effective in controlling allergic rhinitis symptoms before conception. (moderate‑quality evidence) 11, 12, 13, 14
• No clinically meaningful differences in efficacy or safety have been demonstrated among the various intranasal corticosteroids. (moderate‑quality evidence) 11, 12, 13, 14
• Taper to the lowest dose that maintains symptom control to limit systemic exposure. (moderate‑quality evidence) 11, 12, 13, 15

Initiating Therapy During Pregnancy

• Start intranasal budesonide rather than mometasone when a corticosteroid is needed for the first time. (moderate‑quality evidence) 11, 12, 13, 14
• Budesonide is classified as Pregnancy Category B, supported by large human registry data. (high‑quality evidence) 11, 12, 13, 14
• Mometasone remains Pregnancy Category C because of limited human data—not because harm has been demonstrated. (low‑quality evidence) 11, 14

Adjunctive Pharmacologic Options

• Sodium cromolyn (Pregnancy Category B) may be added for patients preferring a non‑steroidal approach, recognizing the need for four‑times‑daily dosing. (moderate‑quality evidence) 12, 13, 16
• Montelukast (Pregnancy Category B) can be incorporated when asthma co‑exists or when prior favorable response has been documented. (moderate‑quality evidence) 12, 13, 16, 17

First‑Trimester Precautions

• Oral decongestants (phenylephrine, pseudoephedrine) should be avoided in the first trimester because of reported links to gastroschisis, small‑intestinal atresia, and cardiac anomalies. (moderate‑quality evidence) 13, 14, 16
• The teratogenic risk rises when oral decongestants are combined with acetaminophen or salicylates. (moderate‑quality evidence) 18, 14

Use Throughout Pregnancy

• Intranasal corticosteroids may be employed safely in all trimesters, given their favorable safety and efficacy profile. (moderate‑quality evidence) 11, 12, 13, 15

Medication Selection Pitfalls

• Do not initiate mometasone when budesonide is available; budesonide has superior human safety documentation. (moderate‑quality evidence) 11, 12, 13, 14
• Do not discontinue an effective mometasone regimen without a clear safety advantage, as switching may destabilize symptom control. (moderate‑quality evidence) 11, 12, 13, 14

Dosing Recommendations

• Prescribe the lowest effective dose; higher doses increase systemic exposure without proportional clinical benefit. (moderate‑quality evidence) 11, 12, 13, 15

Patient Counseling & Administration

• Engage in shared decision‑making, explicitly discussing the benefits and potential risks of each medication option during pregnancy. (moderate‑quality evidence) 11, 12, 13
• Instruct patients on proper nasal spray technique—aiming the spray away from the nasal septum—to minimize local adverse effects such as epistaxis. (moderate‑quality evidence) 19

Allergen Immunotherapy

• Continue pre‑existing allergen immunotherapy without dose escalation during pregnancy; however, do not initiate immunotherapy de novo because of anaphylaxis risk. (moderate‑quality evidence) 11, 12, 13, 15, 16, 17

Safety of Antihistamines During the First Trimester of Pregnancy

General Safety of Second‑Generation Antihistamines

• Guidelines from allergy societies state that second‑generation antihistamines (e.g., cetirizine, loratadine, fexofenadine) have an excellent safety record and are not associated with a significant increase in congenital malformations when used during the first trimester of pregnancy【20】.

Critical Timing Considerations

• The first trimester, corresponding to the organogenesis period, is the window of greatest concern for medication‑related congenital malformations; therefore, safety data for antihistamines are most relevant when evaluated for use in this period【20】.

Specific Risks Associated with Other Antihistamines and Decongestants

• Oral decongestants such as phenylephrine and pseudoephedrine should be avoided in the first trimester because epidemiologic data link them to gastroschisis, small‑intestinal atresia, and cardiac anomalies【20】.
• Hydroxyzine is contraindicated in the first trimester based on animal teratogenicity findings【20】.
• Diphenhydramine has been associated with an increased risk of cleft palate in some studies, although more recent data provide a more reassuring safety profile【20】.

Position of Fexofenadine Within the Evidence Base

• Although fexofenadine has fewer epidemiologic studies than cetirizine and loratadine, existing data show no reports of increased congenital malformations and animal studies demonstrate a lack of teratogenic effects, supporting its use when clinically indicated【20】.